May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Whole Body 18FDG PET-CT Imaging of Systemic Sarcoidosis
Author Affiliations & Notes
  • J. P. Shulman
    The New York Eye Cancer Center, New York, New York
    The New York Eye and Ear Infirmary, New York, New York
  • P. Latkany
    The New York Eye and Ear Infirmary, New York, New York
  • K. J. Chin
    The New York Eye Cancer Center, New York, New York
  • P. T. Finger
    The New York Eye Cancer Center, New York, New York
    The New York Eye and Ear Infirmary, New York, New York
  • Footnotes
    Commercial Relationships  J.P. Shulman, None; P. Latkany, None; K.J. Chin, None; P.T. Finger, None.
  • Footnotes
    Support  The EyeCare Foundation, Inc., New York City, http://eyecarefoundation.org
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 607. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. P. Shulman, P. Latkany, K. J. Chin, P. T. Finger; Whole Body 18FDG PET-CT Imaging of Systemic Sarcoidosis. Invest. Ophthalmol. Vis. Sci. 2008;49(13):607. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To describe systemic sarcoidosis lesions revealed through whole body 18-Fluorodeoxyglucose (FDG) positron emission tomography/computed radiographic tomography (PET/CT) imaging.

 
Methods:
 

We performed a retrospective review of 4 ocular tumor patients evaluated with PET/CT for metastatic disease. Each had a history of or was diagnosed with systemic sarcoidosis. Two were under treatment for conjunctival melanoma and 2 presented with atypical choroidal tumors. We used PET/CT to stage each patient. PET/CT images were studied for presence of increased 18-FDG concentration. Elevated standardized uptake values (SUV) typically greater than or equal to 2.5 were considered positive. High SUV levels indicate increased metabolism (glucose consumption).

 
Results:
 

In all cases, PET-CT revealed increased systemic 18-FDG uptake with SUV values ranging from 1.7 to 5.9. Patient demographics, ocular findings and sites of activity are summarized in the Table. Patients 1 and 2 had a previous diagnosis of systemic sarcoidosis (without clinically apparent ocular involvement), while patients 3 and 4 were newly diagnosed. PET/CT is shown to reveal the presence and distribution of clinically apparent and occult sarcoid granulomas.

 
Conclusions:
 

PET/CT is a powerful imaging modality for staging ocular and nonocular cancers. It has been found to detect synchronous non-ocular primary cancer and inflammatory disease. In this series, PET/CT helped in the diagnosis and staging of patients with systemic sarcoidosis.  

 
Keywords: imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • tumors • imaging/image analysis: clinical 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×